1. Home
  2. CAPR vs SPTN Comparison

CAPR vs SPTN Comparison

Compare CAPR & SPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAPR
  • SPTN
  • Stock Information
  • Founded
  • CAPR 2005
  • SPTN 1917
  • Country
  • CAPR United States
  • SPTN United States
  • Employees
  • CAPR N/A
  • SPTN N/A
  • Industry
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • SPTN Food Distributors
  • Sector
  • CAPR Health Care
  • SPTN Consumer Discretionary
  • Exchange
  • CAPR Nasdaq
  • SPTN Nasdaq
  • Market Cap
  • CAPR 867.6M
  • SPTN 746.4M
  • IPO Year
  • CAPR N/A
  • SPTN N/A
  • Fundamental
  • Price
  • CAPR $13.07
  • SPTN $19.40
  • Analyst Decision
  • CAPR Strong Buy
  • SPTN Hold
  • Analyst Count
  • CAPR 7
  • SPTN 1
  • Target Price
  • CAPR $39.29
  • SPTN $20.00
  • AVG Volume (30 Days)
  • CAPR 1.8M
  • SPTN 298.9K
  • Earning Date
  • CAPR 11-13-2024
  • SPTN 02-13-2025
  • Dividend Yield
  • CAPR N/A
  • SPTN 4.49%
  • EPS Growth
  • CAPR N/A
  • SPTN 9.92
  • EPS
  • CAPR N/A
  • SPTN 1.33
  • Revenue
  • CAPR $23,228,045.00
  • SPTN $9,532,883,000.00
  • Revenue This Year
  • CAPR N/A
  • SPTN N/A
  • Revenue Next Year
  • CAPR $74.85
  • SPTN $2.15
  • P/E Ratio
  • CAPR N/A
  • SPTN $14.60
  • Revenue Growth
  • CAPR 65.33
  • SPTN N/A
  • 52 Week Low
  • CAPR $3.52
  • SPTN $17.74
  • 52 Week High
  • CAPR $23.40
  • SPTN $24.51
  • Technical
  • Relative Strength Index (RSI)
  • CAPR 37.42
  • SPTN 49.87
  • Support Level
  • CAPR $12.25
  • SPTN $19.28
  • Resistance Level
  • CAPR $20.75
  • SPTN $19.74
  • Average True Range (ATR)
  • CAPR 1.62
  • SPTN 0.47
  • MACD
  • CAPR -0.24
  • SPTN 0.09
  • Stochastic Oscillator
  • CAPR 9.65
  • SPTN 66.91

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.

About SPTN SpartanNash Company

SpartanNash Co is a food solutions company that delivers the ingredients. Its principal business activities include, distributing grocery products to a diverse group of independent and chain retailers, its corporate-owned retail stores, and U.S. military commissaries and exchanges; as well as operating a fresh produce distribution network and the Our Family private label brand. The company operates in two segments: Retail and Wholesale. Majority of the revenue is earned from its Wholesale segment which uses a multi-channel sales approach to distribute national brand and private brand products to independent retailers, national accounts, food service distributors, e-commerce providers, and the Company's corporate owned retail stores.

Share on Social Networks: